Amino acid residues affecting drug pump function in Candida albicans - C. albicans drug pump function

Japanese Journal of Medical Mycology

Volumn 47, Issue 4, 2006, Pages 275-281

  Holmes, Ann R ^a   Tsao, Sarah ^a,c   Lamping, Erwin ^a   Niimi, Kyoko ^a   Monk, Brian C ^a   Tanabe, Koichi ^b   Niimi, Masakazu ^b   Cannon, Richard D ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Allelic variation; Antifungal efflux; Candida albicans; Single nucleotide polymorphisms (SNPs)

Indexed keywords

ABC TRANSPORTER; AMINO ACID; ANTIFUNGAL AGENT; FLUCONAZOLE; PROTEIN CDR1P; PROTEIN CDR2P;

CANDIDA ALBICANS; CANDIDIASIS; CELL MEMBRANE; CONCENTRATION RESPONSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MULTIDRUG RESISTANCE; MYCOTIC MENINGITIS; NONHUMAN; OROPHARYNX CANDIDIASIS; PATHOGENICITY; PROTEIN EXPRESSION; PUMP DESIGN; REVIEW; TREATMENT FAILURE;

AMINO ACID SEQUENCE; AMINO ACIDS; ATP-BINDING CASSETTE TRANSPORTERS; CANDIDA ALBICANS; DRUG RESISTANCE, MULTIPLE, FUNGAL;

CANDIDA ALBICANS; FUNGI;

EID: 33751578892     PISSN: 09164804     EISSN: 09164804     Source Type: Journal    
DOI: 10.3314/jjmm.47.275     Document Type: Review

References (49)

1. Stevens DA, Greene SI, Lang OS: Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med 151: 2458-2464, 1991.
2. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M: Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 32: 2092-2098, 1994.
3. Boschman CR, Bodnar UR, Tornatore MA, Obias AA, Noskin GA, Englund K, Postelnick MA, Suriano T, Peterson LR: Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob Agents Chemother 42: 734-738, 1998.
4. White TC, Marr KA, Bowden RA: Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11: 382-402, 1998.
5. Jones JL, Hanson DL, Dworkin MS, Alderton DL, Fleming PL, Kaplan JE, Ward J: Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ 48: 1-22, 1999.
6. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, Jones JL: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 30 Suppl 1: S5-14, 2000.
7. Bertagnolio S, de Gaetano Donati K, Tacconelli E, Scoppettuolo G, Posteraro B, Fadda G, Cauda R, Tumbarello M: Hospital-acquired candidemia in HIV-infected patients. Incidence, risk factors and predictors of outcome. J Chemother 16: 172-178, 2004.
8. Richman DD: HIV chemotherapy. Nature 410: 995-1001, 2001.
9. Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, Haubrich RH, St Clair M, Lanier ER, Hellmann NS, Richman DD: Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther 8: 489-506, 2003.
10. Morschhauser J: The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 1587: 240-248, 2002.
11. Akins RA: An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol 43: 285-318, 2005.
12. Prasad R, Kapoor K: Multidrug resistance in yeast Candida. Int Rev Cytol 242: 215-248, 2005.
13. Sanglard D, Bille J: Current understanding of the modes of action of and resistance mechanisms to conventional and emerging antifungal agents for treatment of Candida infections. In Candida and Candidiasis (R. Calderone, Ed), p.349-383, ASM Press, Washington, 2002.
14. White TC, Holleman S, Dy F, Mirels LF, Stevens DA: Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46: 1704-1713, 2002.
15. Maebashi K, Niimi M, Kudoh M, Fischer FJ, Makimura K, Niimi K, Piper RJ, Uchida K, Arisawa M, Cannon RD, Yamaguchi H: Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients. J Antimicrob Chemother 47: 527-536, 2001.
16. Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martinez M, Calabrese D, Sanglard D, Patterson TF: Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45: 2676-2684, 2001.
17. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J: Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39: 2378-2386, 1995.
18. White TC: Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41: 1482-1487, 1997.
19. Rogers PD, Barker KS: Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrob Agents Chemother 47: 1220-1227, 2003.
20. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM: Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 48: 2124-2131, 2004.
21. Gaur M, Choudhury D, Prasad R: Complete inventory of ABC proteins in human pathogenic yeast, Candida albicans. J Mol Microbiol Biotechnol 9: 3-15, 2005.
22. Sanglard D, Ischer F, Monod M, Bille J: Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 40: 2300-2305, 1996.
23. Niimi M, Niimi K, Takano Y, Holmes AR, Fischer FJ, Uehara Y, Cannon RD: Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance. J Antimicrob Chemother 54: 999-1006, 2004.
24. Ernst R, Klemm R, Schmitt L, Kuchler K: Yeast ATP-binding cassette transporters: cellular cleaning pumps. Methods Enzymol 400: 460-484, 2005.
25. Dean M: The genetics of ATP-binding cassette transporters. Methods Enzymol 400: 409-429, 2005.
26. Dean M, Rzhetsky A, Allikmets R: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11: 1156-1166, 2001.
27. Ishikawa T, Sakurai A, Kanamori Y, Nagakura M, Hirano H, Takarada Y, Yamada K, Fukushima K, Kitajima M: High-speed screening of human ATP-binding cassette transporter function and genetic polymorphisms: new strategies in pharmacogenomics. Methods Enzymol 400: 485-510, 2005.
28. Breier A, Barancik M, Sulova Z, Uhrik B: P-glycoprotein-implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 5: 457-468, 2005.
29. Jones PM, George AM: The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 61: 682-699, 2004.
30. Borges-Walmsley MI, McKeegan KS, Walmsley AR: Structure and function of efflux pumps that confer resistance to drugs. Biochem J 376: 313-338, 2003.
31. De Hertogh B, Carvajal E, Talla E, Dujon B, Baret P, Goffeau A: Phylogenetic classification of transporters and other membrane proteins from Saccharomyces cerevisiae. Funct Integr Genomics 2: 154-170, 2002.
32. Decottignies A, Kolaczkowski M, Balzi E, Goffeau A: Solubilization and characterization of the overexpressed PDR5 multidrug resistance nucleotide triphosphatase of yeast. J Biol Chem 269: 12797-12803, 1994.
33. Nakamura K, Niimi M, Niimi K, Holmes AR, Yates JE, Decottignies A, Monk BC, Goffeau A, Cannon RD: Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters. Antimicrob Agents Chemother 45: 3366-3374, 2001.
34. Saini P, Prasad T, Gaur NA, Shukla S, Jha S, Komath SS, Khan LA, Haq QM, Prasad R: Alanine scanning of transmembrane helix 11 of Cdr1p ABC antifungal efflux pump of Candida albicans: identification of amino acid residues critical for drug efflux. J Antimicrob Chemother 56: 77-86, 2005.
35. Shukla S, Ambudkar SV, Prasad R: Substitution of threonine-1351 in the multidrug transporter Cdr1p of Candida albicans results in hypersusceptibility to antifungal agents and threonine-1351 is essential for synergic effects of calcineurin inhibitor FK520. J Antimicrob Chemother 54: 38-45, 2004.
36. Wada S, Niimi M, Niimi K, Holmes AR, Monk BC, Cannon RD, Uehara Y: Candida glabrata ATP-binding cassette transporters Cdr1p and Pdh1p expressed in a Saccharomyces cerevisiae strain deficient in membrane transporters show phosphorylation-dependent pumping properties. J Biol Chem 277: 46809-46821, 2002.
37. Niimi M, Tanabe K, Wada S, Yamazaki A, Uehara Y, Niimi K, Lamping E, Holmes AR, Monk BC, Cannon RD: ABC transporters of pathogenic fungi: recent advances in functional analyses. Jpn J Med Mycol 46: 249-260, 2005.
38. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A2, 2nd ed. National Committee for Clinical Laboratory Standards, Villanova, Pa. NCCLS document M27-A2, 2002.
39. Schuetzer-Muehlbauer M, Willinger B, Krapf G, Enzinger S, Presterl E, Kuchler K: The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol 48: 225-235, 2003.
40. Niimi K, Harding DR, Parshot R, King A, Lun DJ, Decottignies A, Niimi M, Lin S, Cannon RD, Goffeau A, Monk BC: Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative. Antimicrob Agents Chemother 48: 1256-1271, 2004.
41. Frelet A, Klein M: Insight in eukaryotic ABC transporter function by mutation analysis. FEBS Lett, 2006.
42. Ishikawa T, Onishi Y, Hirano H, Oosumi K, Nagakura M, Tarui S: Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biol Pharm Bull 27: 939-948, 2004.
43. Jha S, Karnani N, Dhar SK, Mukhopadhayay K, Shukla S, Saini P, Mukhopadhayay G, Prasad R: Purification and characterization of the N-terminal nucleotide binding domain of an ABC drug transporter of Candida albicans: uncommon cysteine 193 of Walker A is critical for ATP hydrolysis. Biochemistry 42: 10822-10832, 2003.
44. Jha S, Karnani N, Lynn AM, Prasad R: Covalent modification of cysteine 193 impairs ATPase function of nucleotide-binding domain of a Candida drug efflux pump. Biochem Biophys Res Commun 310: 869-875, 2003.
45. Jha S, Dabas N, Karnani N, Saini P, Prasad R: ABC multidrug transporter Cdr1p of Candida albicans has divergent nucleotide-binding domains which display functional asymmetry. FEMS Yeast Res 5: 63-72, 2004.
46. Shukla S, Saini P, Smriti, Jha S, Ambudkar SV, Prasad R: Functional characterization of Candida albicans ABC transporter Cdr1p. Eukaryot Cell 2: 1361-1375, 2003.
47. Egner R, Bauer BE, Kuchler K: The transmembrane domain 10 of the yeast Pdr5p ABC antifungal efflux pump determines both substrate specificity and inhibitor susceptibility. Mol Microbiol 35: 1255-1263, 2000.
48. Loo TW, Clarke DM: Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J Biol Chem 277: 44332-44338, 2002.
49. Wada S, Tanabe K, Yamazaki A, Niimi M, Uehara Y, Niimi K, Lamping E, Cannon RD, Monk BC: Phosphorylation of Candida glabrata ATP-binding cassette transporter Cdr1p regulates drug efflux activity and ATPase stability. J Biol Chem 280: 94-103, 2005.